Comparative Pharmacology
Head-to-head clinical analysis: FYREMADEL versus VICODIN ES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FYREMADEL versus VICODIN ES.
FYREMADEL vs VICODIN ES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FYREMADEL is a GLP-1 receptor agonist that activates GLP-1 receptors, increasing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner, and slows gastric emptying.
Hydrocodone is a mu-opioid receptor agonist; acetaminophen inhibits cyclooxygenase (COX) and modulates descending serotonergic pathways.
100 mg orally twice daily.
Oral: 1 tablet (7.5 mg hydrocodone/300 mg acetaminophen) every 4-6 hours as needed for pain; maximum 6 tablets per day due to acetaminophen limit.
None Documented
None Documented
Terminal half-life: 12 hours (range 8–16 h) in healthy adults; prolonged in hepatic impairment.
Hydrocodone: terminal half-life approximately 3.3-4.5 hours in adults, extended in hepatic or renal impairment. Acetaminophen: terminal half-life about 2-3 hours.
Renal: 60% unchanged; Biliary/Fecal: 30% as metabolites; 10% other.
Hydrocodone: primarily renal (urine) as unchanged drug and metabolites (O-demethylation and 6-keto-reduction products); ~26% excreted unchanged. Acetaminophen: renal (urine), ~85% as glucuronide and sulfate conjugates, ~2% unchanged.
Category C
Category C
Opioid Analgesic
Opioid Analgesic